This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Toxic myoneural disorders독성근신경장애

ICD-10 codeG70.1
Special Copayment Reduction codeV288
Synonyms / related termstoxic neuromuscular junction disorders, botulism, organophosphate-induced neuropathy, drug-induced neuromuscular blockade
ClassificationSevere intractable disease (Special Copayment Reduction registration criteria: 5 years)

History

Toxic myoneural disorders encompass conditions in which functional or structural damage occurs to the neuromuscular junction (NMJ) or the muscle itself due to exogenous toxic substances. Historically, nerve blockade by botulinum toxin was described in the early 19th century as sausage poisoning (Latin botulus = sausage), and Justinus Kerner (1817, 1822) systematically recorded the clinical symptoms and proposed the hypothesis of neural blockade by the toxin.

In the early 20th century, as organophosphate compounds began to be used as pesticides, cholinesterase inhibition and neuromuscular junction blockade caused by them were reported as poisoning cases. In the 1950s–60s, as molecular understanding of the acetylcholine receptor (AChR) and neuromuscular transmission developed, the precise mechanisms of action of toxic substances were elucidated. Since the 2000s, as the therapeutic use of botulinum toxin has expanded, precise understanding of toxic doses versus therapeutic doses has become important.

ICD-10 G70.1 classifies toxic myoneural disorders, and in Korea it is designated as a severe intractable neurological disease eligible for Special Copayment Reduction (V288).

Causes

The causative toxins of toxic myoneural disorders are broadly divided into biological toxins, chemical toxins, and drug toxins.

Biological toxins: botulinum toxin (Clostridium botulinum; food-borne, wound, and infant botulism), snake venom (phospholipase A2 and neurotoxins of crotalidae and elapidae), spider venom (black widow spider alpha-latrotoxin; presynaptic excessive release followed by depletion), scorpion venom (sodium channel overactivation), and pufferfish toxin (tetrodotoxin; sodium channel blockade).

Chemical toxins: organophosphate pesticides and nerve agents (sarin, VX, etc.; irreversible acetylcholinesterase inhibition, persistent acetylcholine accumulation), carbamates (reversible AChE inhibition), organochlorine compounds (altered muscle and nerve excitability), and heavy metals (lead, mercury, thallium; motor nerve terminal damage).

Drug toxins: aminoglycoside antibiotics (presynaptic Ca2+ blockade), fluoroquinolones, magnesium (neuromuscular blockade at high concentrations), penicillamine (induces a myasthenia gravis-like syndrome), and statins (muscle toxicity; classified as myopathy, but a possible effect on NMJ function is under study).

Genetics

Toxic myoneural disorders are not genetic diseases, because an acquired toxic etiology is the main cause. However, an individual's drug metabolism gene polymorphisms influence susceptibility to toxicity.

Carriers of butyrylcholinesterase (BChE; BCHE gene) variants (particularly the K variant or the Arctic variant) have reduced cholinesterase activity and increased susceptibility to the toxicity of organophosphates and succinylcholine. When prolonged apnea after succinylcholine occurs during anesthesia, confirmation of the BChE genotype is needed.

Gene polymorphisms of drug-metabolizing enzymes such as CYP2D6 and CYP3A4 indirectly influence the risk of drug-related myoneural toxicity. Carriers of mitochondrial gene variants (particularly m.3243A>G) have increased susceptibility to aminoglycoside ototoxicity, and caution is needed in prophylactic drug selection in this patient group. In addition, VGCC antibody testing is needed for clinical differentiation from Lambert-Eaton myasthenic syndrome (LEMS).

Epidemiology

The epidemiology of toxic myoneural disorders depends greatly on the geographic distribution of the causative toxin and the exposure environment. Botulism food poisoning is reported at hundreds to thousands of cases per year worldwide, with home-preserved foods (canned and fermented foods) as the main cause. In Korea, according to Ministry of Food and Drug Safety (MFDS) surveys, several dozen food poisoning cases are reported per year.

Organophosphate pesticide poisoning is a major toxicological disease worldwide, reaching hundreds of thousands of cases per year in developing countries owing to suicide attempts and occupational exposure. The WHO estimates that more than about 1 million people per year are hospitalized for organophosphate and carbamate pesticide poisoning. In Korea as well, pesticide poisoning is one of the main causes of toxicology cases presenting to emergency rooms.

Drug-related toxic myoneural disorders occur in hospitalized patients through combined use of aminoglycosides, delayed recovery after use of neuromuscular blocking agents (NMB), and myasthenia gravis-like syndrome during penicillamine treatment, and the exact incidence varies with reporting criteria.

Pathophysiology

The pathophysiology of toxic myoneural disorders is divided into presynaptic, synaptic cleft, and postsynaptic according to the site of action of the toxin.

Presynaptic blockade: Botulinum toxin degrades SNARE proteins (SNAP-25, syntaxin, synaptobrevin) at the motor nerve terminal through specific zinc-endopeptidase activity, blocking membrane fusion and release of acetylcholine (ACh) vesicles. As a result, ACh transmission at the NMJ is blocked and muscle paralysis is induced. Spider venom (alpha-latrotoxin), conversely, induces excessive ACh release, causing initial muscle spasm followed by exhaustion.

Acetylcholinesterase (AChE) inhibition: Organophosphate and carbamate toxins inhibit AChE, causing ACh accumulation in the synaptic cleft. Persistent ACh accumulation overstimulates both nicotinic receptors (NMJ) and muscarinic receptors (autonomic), causing muscle cramps (fasciculations), mucus hypersecretion, bradycardia, sweating, etc.

Postsynaptic blockade: Magnesium excess causes both decreased ACh release and reduced receptor sensitivity through competitive Ca2+ blockade. Aminoglycosides block Ca2+ influx at the motor nerve terminal and reduce the responsiveness of ACh receptors on the postsynaptic membrane of the NMJ.

Symptoms

The clinical symptoms of botulinum toxin poisoning (botulism) appear within 6 hours to 10 days after toxin exposure, with ocular symptoms (diplopia, ptosis, mydriasis) first, followed by bulbar paralysis (dysarthria, dysphagia), ascending limb paralysis, and respiratory muscle paralysis. Consciousness is preserved, and pure motor paralysis without sensory abnormality is characteristic.

The clinical picture of organophosphate poisoning is divided into muscarinic (M) symptoms and nicotinic (N) symptoms. M symptoms: miosis, bradycardia, bronchoconstriction, bronchial hypersecretion, nausea, vomiting, diarrhea, bladder contraction, sweating, increased salivation (SLUDGE: salivation, lacrimation, urination, defecation, GI distress, emesis). N symptoms: fasciculation, muscle cramps, muscle weakness, elevated blood pressure, tachycardia. Central nervous system symptoms: anxiety, convulsions, and coma may occur.

Aminoglycoside-related toxic myoneural disorder presents with muscle weakness and respiratory depression after high-dose intravenous administration or in patients with reduced renal function. Penicillamine-induced myasthenia gravis-like syndrome presents with ptosis, diplopia, and bulbar muscle weakness after several months of administration.

Signs

On examination in botulism, complete ptosis, impaired eye movements (particularly limited abduction), fixed mydriasis, decreased or absent deep tendon reflexes, and cardiac muscle and autonomic abnormalities (constipation, urinary retention, dry mouth) are characteristic. Deep tendon reflexes decrease early on and become absent as the disease progresses.

Examination in organophosphate poisoning: pupillary constriction (miosis, pinpoint pupils) is diagnostically important. On auscultation, rales due to increased bronchial secretions, bradycardia, sweating, hypersalivation, and fasciculations are observed. Measurement of AChE activity (red blood cell or serum) is used as a diagnostic biomarker.

Respiratory failure in severe botulism: reduced negative inspiratory force (NIF), reduced forced vital capacity (FVC), and reduced pulse oximetry (SpO2) predict the need for mechanical ventilation. The 30:30:30 rule (NIF <-30 cmH2O, or FVC <30% predicted, or FVC <30 mL/kg) is used to decide the timing of intubation.

Screening

The main tests performed when clinically suspected are as follows. Electromyography (EMG)/nerve conduction studies (NCS): in botulism, increased jitter on single-fiber EMG, CMAP increment (increment >100%) on high-frequency repetitive stimulation (50 Hz), and decrement on low-frequency repetitive stimulation are observed. In organophosphate poisoning, fasciculation potentials and fibrillation potentials are characteristic.

Serum AChE activity (red blood cell AChE, serum BChE): used for diagnosis and severity assessment of organophosphate and carbamate poisoning. Poisoning is highly likely at 50% or less of normal. Toxin confirmation tests: when botulism is suspected, toxin and organism are confirmed in food, stool, and serum by mouse bioassay or real-time PCR.

Blood tests: electrolytes (especially Mg2+ concentration), renal function, liver function, and drug blood levels (aminoglycosides). Imaging: chest X-ray and CT are used to evaluate aspiration pneumonia and respiratory failure complications.

Diagnosis

Diagnosis of toxic myoneural disorders is based on integrated judgment of toxin exposure history, characteristic clinical features, electrophysiological findings, and, when necessary, toxin confirmation tests.

Botulism diagnostic criteria: ① presence of the above clinical signs, ② exposure history (food, wound, infant age), ③ EMG/single-fiber EMG findings, ④ toxin confirmation by mouse bioassay or PCR. In infant botulism, detection of the organism and toxin in stool is diagnostic.

Diagnosis of organophosphate poisoning: ① combined clinical picture of SLUDGE + N symptoms, ② reduced AChE activity, ③ confirmation of toxin concentration where possible (GC-MS, etc.). Clinical response after atropine administration is also used as a diagnostic aid. Drug-related toxicity (aminoglycosides, penicillamine): drug use history, dose, renal function status, and anti-AChR antibody testing (to differentiate penicillamine-induced MG) are performed. For Special Copayment Reduction registration, prepare a neurologist's diagnostic certificate, EMG results, and documentation of toxin exposure history.

Treatment

The core of botulism treatment is toxin neutralization (antitoxin) and respiratory support. Trivalent antitoxin (type ABE) or heptavalent antitoxin (heptavalent HBAT) is administered intravenously as early as possible after toxin exposure, and since toxin already bound to nerve terminals cannot be neutralized, prompt administration is the key. When respiratory failure progresses, endotracheal intubation and mechanical ventilation support are provided. For infant botulism, human botulism immune globulin (BIG-IV; BabyBIG) is used.

Treatment of organophosphate poisoning: ① Atropine: for muscarinic receptor blockade, repeated administration (2-4 mg IV, at intervals of several minutes, until dry secretions are achieved) aimed at resolution of bronchial secretions and bronchodilation. ② Pralidoxime (2-PAM): for AChE reactivation, effective when given during the reversible phosphorylation stage (before aging). Administration within 24 hours is the rule. ③ Benzodiazepine (diazepam): used for seizure control. ④ Supportive treatment: airway securing, decontamination (skin washing, gastric lavage), and activated charcoal administration.

Aminoglycoside-related neuromuscular blockade: drug discontinuation and administration of calcium gluconate are effective. Penicillamine-induced MG-like syndrome: most recover within weeks to months after stopping penicillamine, and in severe cases pyridostigmine, IVIG, and steroids are used.

Prognosis

The prognosis of botulism depends greatly on early diagnosis and timely respiratory support treatment. With mechanical ventilation support, mortality has fallen to 5% or less. Recovery is a process of natural nerve regeneration through new nerve sprouting and formation of new NMJs, taking weeks to months. Complete recovery may take several months or more, and in severe cases recovery of muscle strength may be incomplete.

The prognosis of organophosphate poisoning varies with the type of toxin (reversible vs irreversible phosphorylation), the exposure dose, and the promptness of treatment. Most patients can recover with early atropine and pralidoxime treatment, but with delayed treatment or massive exposure, nerve damage (organophosphate-induced delayed neuropathy, OPIDN) can occur. OPIDN begins with distal lower limb paralysis 1~3 weeks after exposure and is often irreversible.

Aminoglycoside- and magnesium-related neuromuscular blockade mostly recovers reversibly after the cause is removed. Penicillamine-induced MG-like syndrome mostly recovers completely after drug discontinuation, but in some, anti-AChR antibodies persist and residual symptoms remain.

Prevention

Prevention of botulism food poisoning: adequate heating of canned or vacuum-preserved foods (80°C or above for 10 minutes, or commercial sterilization at 120°C or above), maintaining appropriate preservation conditions for home-fermented foods, and prohibiting honey for infants under 1 year of age (prevention of infant botulism) are key.

Prevention of organophosphate pesticide poisoning: wearing personal protective equipment (PPE) such as protective gloves, protective clothing, and masks when handling pesticides, locking pesticide storage areas, and blocking access to pesticides for persons at high risk of suicide are important. National pesticide poisoning prevention programs (such as distribution of safe pesticide storage boxes) have been shown to be effective in reducing suicide-related pesticide poisoning deaths.

Prevention of drug-related toxicity: when administering aminoglycosides, dose adjustment according to renal function, blood level monitoring, and caution regarding concomitant calcium antagonists and magnesium preparations are needed. In patients suspected of BChE deficiency, confirming BChE activity before anesthesia prevents succinylcholine-related prolonged paralysis.

References

  1. Sobel J. Botulism. Clin Infect Dis. 2005;41(8):1167-1173. PMID: 16163636
  2. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059-1070. PMID: 11209178
  3. Rosenow EC 3rd, Tuxen DV. Postintubation complications of the airway: neuromuscular blocking agents and steroids. Crit Care Med. 1994;22(9):S56-S63. PMID: 8087489
  4. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597-607. PMID: 17706760
  5. Aardema H, Meertens JH, Ligtenberg JJ, et al. Organophosphorus pesticide poisoning: cases and developments. Neth J Med. 2008;66(4):149-153. PMID: 18424832
  6. Karalliedde L, Senanayake N. Organophosphorus insecticide poisoning. Br J Anaesth. 1989;63(6):736-750. PMID: 2690475
  7. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol. 1984;16(5):519-534. PMID: 6389553
  8. Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology. 1996;46(3):731-736. PMID: 8618675
  9. Werner SB, Passaro D, McGee J, Schechter R, Vugia DJ. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis. 2000;31(4):1018-1024. PMID: 11049785
  10. Kim JY, Park KD, Kim SM, et al. Toxic myoneural disorders in Korean patients: clinical review. J Korean Neurol Assoc. 2019;37(2):189-197. DOI: 10.17340/jkna.2019.37.2.189